Edwards Lifesciences Stock Forecast, Price & News

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EW shares have increased by 27.8% and is now trading at $84.09.
View which stocks have been most impacted by COVID-19.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Edwards Lifesciences.

Wall Street analysts have given Edwards Lifesciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Edwards Lifesciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Edwards Lifesciences.

Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings data on Wednesday, October, 21st. The medical research company reported $0.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.06. The medical research company earned $1.14 billion during the quarter, compared to analyst estimates of $1.08 billion. Edwards Lifesciences had a return on equity of 29.00% and a net margin of 18.18%.
View Edwards Lifesciences' earnings history.

Edwards Lifesciences shares split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its FY20 earnings guidance on Wednesday, October, 21st. The company provided EPS guidance of $1.85-1.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.84.

20 Wall Street analysts have issued twelve-month price objectives for Edwards Lifesciences' shares. Their forecasts range from $51.67 to $105.00. On average, they expect Edwards Lifesciences' share price to reach $87.72 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price.
View analysts' price targets for Edwards Lifesciences.

Edwards Lifesciences saw a drop in short interest in October. As of October 30th, there was short interest totaling 4,980,000 shares, a drop of 29.7% from the October 15th total of 7,080,000 shares. Based on an average daily volume of 2,540,000 shares, the short-interest ratio is presently 2.0 days.
View Edwards Lifesciences' Short Interest.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD), STERIS (STE) and Varian Medical Systems (VAR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), The Home Depot (HD), salesforce.com (CRM), The Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.47%), State Street Corp (4.29%), Sands Capital Management LLC (1.94%), Jackson Square Partners LLC (0.97%), UBS Asset Management Americas Inc. (0.92%) and Fisher Asset Management LLC (0.83%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link.
View institutional ownership trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, First Trust Advisors LP, State of Tennessee Treasury Department, Nuveen Asset Management LLC, AQR Capital Management LLC, State Street Corp, BlackRock Inc., and Point72 Asset Management L.P.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, and Scott B Ullem.
View insider buying and selling activity for Edwards Lifesciences.

EW stock was acquired by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, CIBC Private Wealth Group LLC, Jupiter Asset Management Ltd., AustralianSuper Pty Ltd, Jennison Associates LLC, UBS Asset Management Americas Inc., Raymond James & Associates, and Envestnet Asset Management Inc..
View insider buying and selling activity for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EW stock can currently be purchased for approximately $84.09.

Edwards Lifesciences has a market capitalization of $52.41 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $1.86 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe.

The official website for Edwards Lifesciences is www.edwards.com.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]